PD-L1 cell nanovesicle drug loaded with Ai tablets and its preparation and application

By constructing PD-L1 cell nanovesicles and loading wormwood tablets, combined with temperature-sensitive hydrogel, the problem of excessive inflammatory response and difficulty in PD-L1 exosome production control in skin wound healing is solved, and the drug is efficient Absorption and healing promote, significantly accelerating the wound healing process.

CN114903977BActive Publication Date: 2024-11-29GUANGDONG PHARMA UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210703973.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-06-21
Publication Date
2024-11-29
Estimated Expiration
2042-06-21

AI Technical Summary

Technical Problem

Prior Art During the healing of skin wounds, excessive inflammatory responses will delay tissue healing and lead to fibrosis and scar formation, and PD-L1 exosomes are difficult to produce and control, and PD-L1 tablets lack joint preparation in skin pharmacology applications. medicine.

Method used

PD-L1 cell nanovesicles were prepared by constructing cell lines that overexpress the PD-L1 gene in lentiviral vectors, and the moxa tablets were loaded into these vesicles, combining a temperature-sensitive hydrogel as a carrier to stabilize the encapsulation and release the drug , promotes skin healing.

Benefits of technology

The synergistic anti-inflammatory effect of PD-L1 protein and moxa tablets is achieved, which improves drug absorption and bioavailability, promotes tissue regeneration and ideal repair, reduces the limitations of a single treatment method, and significantly accelerates the wound healing process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114903977B_ABST
    Figure CN114903977B_ABST
Patent Text Reader

Abstract

The present invention provides a PD-L1 cell nanovesicle drug loaded with Ai tablets and its preparation and application. The present invention constructs a HEK 293T transfected cell line that stably expresses the PD-L1 gene, thereby preparing PD-L1 cell nanovesicles, and then loading a low dose of Ai tablets and preparing them into hydrogels. The process of the present invention is simple, the expression of the target protein is efficient and stable, and the prepared nanomedicine has the advantages of good biocompatibility, low toxicity, and high drug utilization rate; the drug effect is more significant than that used alone; the nanomedicine is embedded in a thermosensitive hydrogel, which is easy to use and the nanomedicine can be released sustainably and stably. In vitro experiments show that it can inhibit the proliferation of immune cells and promote the migration of skin cells. The scald model confirms that the nanomedicine of PD-L1 protein and Ai tablets has the effect of synergistic anti-inflammatory and promoting overall drug absorption, and accelerates wound healing. The present invention has opened up a new way for the effective treatment of diseases such as skin trauma.
Need to check novelty before this filing date? Find Prior Art

Description

Field of the invention:

[0001] The present invention belongs to the field of skin wound treatment in the field of medical technology. Specifically, the present invention provides a PD-L1 cell nanovesicle drug loaded with moxa tablets and its preparation and application. Background technology:

[0002] Wound healing is a metabolically complex process that relies on the complex interactions and collaborative work of a series of inflammatory cells, chemokines, cytokines, matrix molecules, and nutrients to restore the injured skin to its intact barrier function. In the repair process of wound healing, inflammation during the hemostatic and inflammatory phases effectively prevents wound infection, but during the proliferation and remodeling phases, persistent and excessive inflammatory responses will delay the healing process of tissue wounds and easily lead to tissue fibrosis and even the formation of hypertrophic scars. Therefore, the regulation of the skin's immune environment and immunosuppressive therapy play a key role in the proliferation phase of wound healing. We try to achieve ideal wound healing and epidermal repair by inhibiting the overactivity of immune cells in the wound to inhibit excessive inflammatory responses.

[0003] Programmed Death Ligand-1 (PD-L1) is a negative regulator that can inhibit the proliferation and activation of T cells to a certain extent by activating the PD-1 / PD-L1 immune checkpoint pathway, play an immunosuppressive role, and effectively inhibit the production of inflammatory factors. At present, multiple studies have shown that PD-L1 plays a significant therapeutic effect in reducing immune rejection reactions after transplantation operations such as skin, liver and heart. In addition, it has been reported that PD-L1 exosomes secreted by genetically engineered cells or IFN-γ stimulated cells can be used as a new type of immunosuppressant to promote wound healing in skin excision wound models, which fully demonstrates the potential of PD-L1 in skin repair. However, PD-L1 exosomes have the disadvantages of being difficult to quantify and difficult to control the PD-L1 content. The present invention constructs a cell transfection strain that overexpresses the PD-L1 gene through a lentiviral vector, and the exosome-like cell membrane vesicle structure prepared from this source is called a cell nanovesicle (NVs), and its preparation process is more efficient, convenient, and fast, and the PD-L1 protein can be stably overexpressed.

[0004] Artemisia balsamifera (BO) is a volatile crystal extracted from the fresh leaves of Blumea balsamifera (L.) DC, a plant of the Asteraceae family. It is the only plant source of Artemisia balsamifera. In the early stage, our research group has accumulated a certain scientific research foundation on the skin pharmacology of Blumea balsamifera. It was found that Blumea balsamifera oil can reduce the water content of burn tissue to shorten the scab formation time, reduce the content of factors such as IL-1, TNF-α and MDA in serum, increase the activity of SOD, upregulate the expression of growth factors, and effectively promote the formation of collagen fibers at the wound site, thereby accelerating the healing of burn wounds (Fan, ZW, Pang, YX, Wang, K., et al. Blumea balsamifera Oil for the Acceleration of Healing of Burn Injuries[J]. Molecules, 2015, 20(9): 17166-17179.). It was further found that Blumea balsamifera oil can reduce the number of inflammatory cells and significantly increase the content of hydroxyproline, effectively improving the contraction and closure of wounds in mice with skin defects and improving the wound healing rate (Pang, Y., Wang, D., Hu, X., et al. Effect of volatile oil from Blumea balsamifera Balsamifera (L.) DC. leaves on wound healing in mice [J]. Journal of Traditional Chinese Medicine, 2014, 34 (6): 716-724.); We have reported that the main components of Blumea balsamifera can promote the discharge of photoproduct 8-OHdG, downregulate the mRNA level of IL-6 in photodamaged tissues, and play an anti-inflammatory role to promote wound healing in UVB-irradiated mice (Li Xiaoting, Wang Dan, Pang Yuxin, et al. Effects of L-borneol on skin photodamage in mice after UVB irradiation [J]. Modern Chinese Medicine, 2017, 19 (04): 518-524.). All of the above confirm that the anti-inflammatory and antibacterial effects of Blumea balsamifera are very significant, and it is a drug with great potential to promote tissue regeneration and repair treatment of inflammatory wounds such as deep second-degree burns.

[0005] However, there is currently no drug prepared by combining the two. Summary of the invention:

[0006] The applicant combines PD-L1 protein and Ai tablets to prepare nano drugs. On the one hand, it maintains the stability of Ai tablets, promotes the absorption of the whole drug and improves the bioavailability. On the other hand, it can play a synergistic anti-inflammatory role and promote the regeneration and ideal repair of tissues. In order to facilitate the application of nano drugs, it is necessary to combine a carrier material that can stably encapsulate the cell nano vesicles. Thermosensitive hydrogels have significant advantages in drug delivery, 3D cell culture, etc., and can stably encapsulate molecular drugs, continuously release and maintain their activity. Compared with traditional hydrogels, thermosensitive hydrogels have the advantage of being able to sense changes in ambient temperature and undergo sol-gel transition, better mix with nano vesicle drugs evenly in a low-temperature flow state, and better maintain their activity and facilitate storage and transportation. When applied to the wound, the temperature rises and gelation occurs, and the gel network formed can be used as a good biological scaffold to encapsulate nano drugs. Furthermore, the hydrogel applied to the wound isolates the external environment to a certain extent, prevents infection, avoids water and heat loss, keeps the wound moist and relieves pain, which is beneficial to the repair of the wound.

[0007] On the one hand, the present invention provides a PD-L1 cell nanovesicle drug loaded with an Ai tablet, wherein the drug comprises a PD-L1 cell nanovesicle, and the PD-L1 cell nanovesicle is loaded with an Ai tablet.

[0008] Furthermore, the drug consists of PD-L1 cell nanovesicles and moxa tablets in a weight ratio of 10:1-10, preferably 10:10.

[0009] Furthermore, the PD-L1 cell nanovesicles are obtained by constructing a PD-L1 gene transfected cell line, amplifying, lysing, grinding tissue, centrifuging, and gradient filtration to obtain a vesicle-like cell membrane structure.

[0010] Furthermore, the preparation method of the PD-L1 cell nanovesicles includes: using PEI transfection reagent, mouse / human CD274 gene lentiviral cDNA expression plasmid and packaging plasmid to prepare a recombinant lentiviral vector, infecting the target cells to construct a transfected cell line that stably overexpresses the PD-L1 gene; after culture and amplification, using HM lysis buffer to lyse the cells, using a tissue grinder to fully grind and break the cells, 5000 rpm, 4°C, centrifuge for 10 min to remove the cell nucleus and other impurities; 12000 rpm, 4°C, centrifuge for 10 min to obtain a cell membrane precipitate; then filtering through 0.45μm, 0.22μm and 0.11μm pore size filter membranes to compress into a vesicle-like cell membrane structure, to obtain PD-L1 cell nanovesicles; using Bradford protein quantification reagent to determine the protein amount and adjust the concentration of PD-L1 cell nanovesicles to 1 mg / ml.

[0011] Furthermore, during the preparation process, the moxa tablets were ground into powder, 10 mg of moxa tablets were weighed, dissolved in 10 μL of DMSO, 1 mL of PBS was added gradually, and the centrifuge tube was ultrasonicated for 5 minutes to help dissolution until the total volume was 10 mL, to obtain a 1 mg / mL moxa tablet solution.

[0012] Furthermore, the drug was prepared by the following method: 1 mg / ml PD-L1 cell nanovesicles were mixed with 1 mg / ml Ai tablet solution, and Ai tablets were loaded into the cell nanovesicles using a MicroPulser electroporator at 300V and 150μF. After incubation on ice for 30 minutes, the unloaded Ai tablets were removed by centrifugation at 13500rpm and 4°C for 10 minutes, and the drug was resuspended in PBS.

[0013] Furthermore, the drug also contains a pharmaceutically acceptable excipient, preferably a coated or smeared carrier, more preferably a thermosensitive hydrogel, and even more preferably Pluronic F-127 thermosensitive hydrogel; preferably, the volume ratio of the nano drug solution to the 30% thermosensitive hydrogel is 1:2.

[0014] On the other hand, the present application provides the use of the above-mentioned drug in the preparation of a drug for promoting wound healing or treating skin trauma.

[0015] Furthermore, the wound or trauma is a burn, diabetic foot or a cut.

[0016] On the other hand, the present application provides a method for preparing the above-mentioned drug, the method comprising:

[0017] (1) Recombinant lentivirus was prepared using PEI transfection reagent, mouse / human CD274 gene lentiviral cDNA expression plasmid, psPAX2 and VSVG packaging plasmid, and HEK 293T cells were infected to construct a transfected cell line that stably overexpressed the PD-L1 gene;

[0018] (2) After the transfected cell line was cultured and expanded, the cells were lysed using HM lysis buffer, fully ground with a tissue grinder to break the cells, and then centrifuged twice, sonicated, and gradient filtered;

[0019] (3) using a MicroPulser electroporator to load the moxa tablets into the cell nanovesicles, incubate, centrifuge, and resuspend;

[0020] (4) adding an appropriate volume of PBS containing PD-L1 cell nanovesicles loaded with Ai tablets to the thermosensitive hydrogel and mixing evenly;

[0021] The preferred hydrogel concentration in step (4) is 20%, and the more preferred step (4) is: weigh 30 g of thermosensitive hydrogel Pluronic F-127 powder, add 100 mL of PBS, place on a stirrer in a 4°C refrigerator and stir overnight to completely dissolve the thermosensitive hydrogel, and the final concentration of the thermosensitive hydrogel is 30%; under 4°C, add an appropriate amount of nano drug solution to the thermosensitive hydrogel and stir evenly to make the final concentration of the hydrogel 20%.

[0022] The moxa tablets in the present application refer to volatile crystals extracted and processed from the fresh leaves of Blumea balsamifera (L.) DC of the Asteraceae family, which are white crystals; they can be purchased commercially or prepared by methods known in the art.

[0023] The particle size of the PD-L1 cell nanovesicles in the present application is 100-220 nm, and the internal hydrophobic space load can be used to load moxa tablets.

[0024] Those skilled in the art can select the excipients such as the carrier, thermosensitive hydrogel, etc. applied or smeared in the present application according to conventional knowledge of pharmacy, without being limited to specific models.

[0025] The drug of the present application is preferably used continuously, preferably for more than three days.

[0026] Beneficial effects:

[0027] (1) Biosafety: The obtained nanomedicine loaded with PD-L1 cell nanovesicles is a cell membrane phospholipid structure derived from cells and has good biocompatibility.

[0028] (2) Bioavailability: The drug size is 100-220nm. Nanoparticles are easier to pass through physiological barriers and have better transdermal absorption effects. In addition, moxa tablets can promote the absorption of the entire drug. Hydrogels can maintain the activity of nanodrugs and release them continuously and stably.

[0029] (3) Targeting: Nanomedicines are rich in PD-L1 protein and are easier to target immune cells in skin tissue, playing an immunosuppressive and anti-inflammatory role.

[0030] (4) Complementary therapeutic mechanisms: After the PD-L1 cell nanovesicles are loaded with moxa tablets, the combined effects of the drugs are exerted, reducing the limitations of a single treatment method and enhancing the efficacy. Description of the drawings:

[0031] Figure 1 .Preparation and characterization of PD-L1 cell nanovesicles loaded with moxa tablets. Figure 1A. Observation of subcellular localization of PD-L1 protein in cells. Figure 1 B. PD-L1 mRNA overexpression level results. Figure 1 CE. Transmission electron microscopy images (C), particle size distribution (D) and Zeta potential (E) results of different cell nanovesicles. Figure 1 F. Expression of PD-L1 protein in cells and cell nanovesicle samples. Data are presented as mean ± standard error (Mean ± SEM) of three independent experiments. (* indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001, ns indicates P > 0.05, not significant).

[0032] Figure 2 .Study on the in vitro activity of PD-L1 cell nanovesicles loaded with moxa tablets. Figure 2 A. Uptake of cellular nanovesicles by Jurkat cells (scale bar: 5 μm). Figure 2 BE.PD-L1 cell nanovesicles inhibit the proliferation of PBMC and T cells. (B: Flow cytometry representative diagram of inhibition of T cell and PBMC proliferation, DE: Data statistics of inhibition of T cell (D) and PBMC (E) proliferation, C: Comparison of the inhibitory effect of cell nanovesicles on PBMC and T cell proliferation) Figure 2 FG. PD-L1 cell nanovesicles promote the migration of HaCaT cells (F: data statistics after quantification of the scratch area, G: representative graph of the scratch test results of each group, scale: 100μm). Data are expressed as mean ± standard error (Mean ± SEM) of three independent experiments. (* indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001, ns indicates P > 0.05, not significant).

[0033] Figure 3 .Preparation and characterization of thermosensitive hydrogels embedded with nanodrugs. Figure 3 A. Gelation of thermosensitive hydrogel (AⅠ: gelation after standing at room temperature; A II: thermosensitive hydrogel at 4°C; A III: gelation after applying to the wound of mouse skin; Figure 3 B. Internal microscopic morphology image taken by scanning electron microscope (scale 5μm). Figure 3 C. Rheological test results of thermosensitive hydrogel. Figure 3DE. HaCaT cells uptake of cell nanovesicles in thermosensitive hydrogels (scale: 5 μm, D: laser confocal microscopy images of cell uptake after incubation for different time periods; E: statistical graph of data after fluorescence quantification). Data are expressed as mean ± standard error (Mean ± SEM) of three independent experiments. (* indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001, ns indicates P > 0.05, not significant).

[0034] Figure 4 .Thermosensitive hydrogels encapsulating nanodrugs promote wound healing. Figure 4 AB. Wound healing status of mice after treatment with different nanodrug hydrogels (A) and calculation results of healing rate (B). Figure 4 C. Pathological analysis results (scale bar: 200 nm, white arrow: horn cyst, black arrow: skin appendage).

[0035] (** indicates P<0.01).

[0036] Figure 5 .Thermosensitive hydrogels encapsulating nanodrugs can exert synergistic inflammatory effects. Figure 5 AB. CD8 in lymph nodes after treatment with thermosensitive hydrogels encapsulating nanodrugs + T cell activation (A: representative graph of flow cytometry analysis, B: statistical graph of data). Figure 5 C. CD8 in spleen after treatment with thermosensitive hydrogel encapsulating nanodrugs + T cell activation. Figure 5 D. Changes in the levels of inflammatory factors in wound skin after treatment with thermosensitive hydrogels encapsulating nanomedicines. Data are presented as mean ± standard error (Mean ± SEM) of three independent experiments. (* indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001, ns indicates P > 0.05, not significant). Specific implementation method:

[0037] Example 1 Basic experimental process

[0038] 1. Methods and Materials

[0039] 1. Construction of HEK 293T cell line overexpressing PD-L1

[0040] 1.1 Construction of PD-L1 (OFP-tag) lentiviral plasmid

[0041] Human CD274 gene lentiviral cDNA expression plasmid (C-OFP Spark tag, Sino Biologocal Inc.) (Genebank Ref. ID: NM_014143.2), mouse CD274 gene lentiviral cDNA expression plasmid (C-OFP Spark tag, Sino Biologocal Inc.) (Genebank Ref. ID: NM_021893.2), packaging plasmid psPAX2, packaging plasmid VSVG, among which the in vitro activity study of the drug and the experiment on the uptake of cell nanovesicles in thermosensitive hydrogels by HaCaT cells used human PD-L1 cell nanovesicles, and other experiments used mouse PD-L1 cell nanovesicles.

[0042] The OFP vector and mouse / human CD274 gene lentiviral cDNA expression plasmid were double-digested with restriction endonucleases EcoRⅠ and NotⅠ at the same time, incubated in a water bath at 37℃ for 4h, and the digested products were separated by 0.8% agarose gel electrophoresis and the relevant fragments were recovered by gel. T4 DNA quick ligase was used to incubate in a water bath at 25℃ for 1h, and the ligation products were transformed into DH5α competent cells and inoculated into LB plate medium containing ampicillin (Amp) for overnight culture. A single colony was picked from the plate medium, incubated overnight on a shaking table, and the plasmid was extracted using a large extraction plasmid kit (Tiangen Biochemical Technology Co., Ltd.).

[0043] 1.2 Transfection

[0044] HEK 293T cells were transfected with human CD274 gene lentiviral cDNA expression plasmid (C-OFP Spark tag) or mouse CD274 gene lentiviral cDNA expression plasmid (C-OFP Spark tag) using PEI reagent. After 48 hours of gene manipulation, cells were enriched: at 4×10 5 Add 10 μg of mouse / human CD274 gene lentiviral cDNA expression plasmid, 5 μg of packaging plasmid psPAX2 and 5 μg of packaging plasmid VSVG to HEK 293T cells per mL, and add 5 μL of PEI storage solution for every 2 μg of plasmid; when infecting cells, add 1×10 5 Recombinant lentivirus solution diluted in PBS gradient and 8 μg / mL Polybrene were added to HEK 293T cells with a concentration of 1 μg / mL, and then 5 μg / mL puromycin was used for selection.

[0045] 1.3 Characterization

[0046] The cell membrane was stained with WGA350 dye, and the PD-L1 protein was localized by laser confocal microscopy. Total cell mRNA was extracted using the standard TRIzol protocol, and the RNA concentration and purity were determined. cDNA was prepared using a reverse transcription kit, and qPCR reactions were performed using a qPCR kit and a PCR instrument. -ΔΔCT Methods Relative quantitative data were analyzed to detect overexpression of mPD-L1 RNA. The primer sequences are as follows:

[0047]

[0048] 2. Preparation and characterization of PD-L1 cell nanovesicles loaded with Ai tablets

[0049] 2.1 Isolation of PD-L1 Cell Nanovesicles

[0050] The cells were lysed using HM lysis buffer, and the cell suspension was added to a tissue grinder and fully ground. The cells were centrifuged at 5000 rpm for 10 min, and the cell nuclei and proteins were removed at 4°C. The supernatant was centrifuged at 13500 rpm and 4°C for 10 min, and the precipitate was resuspended in PBS. The cell nanovesicles were sonicated for 5 s to obtain a uniformly dispersed vesicle suspension, and the cell nanovesicles were filtered using a porous filter membrane at 0.45 μm, 0.22 μm, and 0.11 μm, respectively.

[0051] 1-2 mL of HM lysis buffer (250 mM sucrose, 1.02 mM EDTA, 20.02 mM HEPES, pH = 7.4) was added to each 10 cm dish of cells. The centrifugation parameters were 5000 rpm, 10 min, 4°C, and the supernatant was taken; 13500 rpm, 10 min, 4°C, and the precipitate was taken. The ultrasonic parameters were 50% power, 5 s. The pore sizes of the gradient filtration membranes were 0.45 μm, 0.22 μm, and 0.11 μm.

[0052] 2.2 Preparation of Ai tablets stock solution

[0053] After grinding the moxa tablets into powder using a mortar, weigh 10 mg of moxa tablets, dissolve in 10 μL DMSO, and gradually add 1 mL of PBS to a total volume of 10 mL. After each addition of PBS, sonicate the centrifuge tube for 5 minutes to help dissolve, and finally obtain a 1 mg / mL moxa tablet solution. Filter twice with a 0.22 μm filter membrane in a clean bench.

[0054] 2.3 PD-L1 Cell Nanovesicles Loaded with Ai Tablets

[0055] 1 mg / ml PD-L1 cell nanovesicles were mixed with 1 mg / ml Ai tablet solution, and Ai tablets were loaded into the cell nanovesicles using a MicroPulser electroporator at 300 V and 150 μF. After 30 min on ice, the unloaded Ai tablets were removed by centrifugation at 13500 rpm and 4°C for 10 min, and the PD-L1 cell nanovesicles loaded with Ai tablets were resuspended in PBS to obtain nanodrugs.

[0056] 2.4 Characterization

[0057] The nanovesicles were morphologically examined using a scanning transmission electron microscope, and the particle size distribution and Zeta potential of the vesicles were detected using a nanoparticle size and Zeta potential analyzer. The total cell protein was extracted using RIPA lysis buffer, and after quantitative heating denaturation, the target protein was separated using 8% SDS-PAGE to identify the overexpression of PD-L1 protein. The main antibodies used for Western blot analysis were Anti-OFP antibody (1:1000, 15214-1-AP, ChromoTek) and Anti-PD-L1 antibody (1:1000, 8478, Invitrogen).

[0058] 3. Cell experiments

[0059] 3.1 Cell lines

[0060] The human immortalized epidermal cell line (HaCaT) was cultured in DMEM supplemented with 10% FBS, and the human peripheral blood leukemia cell line (Jurkat) was cultured in RPMI-1640 medium supplemented with 10% FBS.

[0061] 3.2 Observation of Jurkat cell uptake of nanomedicine

[0062] The cell membrane was stained with WGA350 dye, and the uptake of cellular nanovesicles by Jurkat cells was observed using laser confocal microscopy.

[0063] 3.3 Detection of the effect of nanomedicine on immune cells

[0064] PBMCs and T cells were isolated from fresh blood using conventional methods, and the cells were labeled with 5 μM CFSE. The proliferation of PBMCs and T cells was analyzed by flow cytometry.

[0065] 3.4 Detection of the effects of nanomedicine on skin cells

[0066] HaCaT cells were used for scratch test to detect the effect of nanomedicine on skin cell migration. After adding nanomedicine, the cells were incubated for 36 hours, photographed with an optical microscope, and the cell-free area was quantified using Image J software. The migration rate was calculated as follows:

[0067] Mobility (%) = scratch area t=0 -Scratched area t=36 / Scratch area t=0 x100%(1)

[0068] 4. Embedding Nanodrugs into Thermosensitive Hydrogels and Characterization

[0069] 4.1 Embedding Nanodrugs into Thermosensitive Hydrogels

[0070] Weigh 30 g of thermosensitive hydrogel (Pluronic F-127) powder, add 100 mL of PBS, and stir overnight on a stirrer in a 4°C refrigerator to completely dissolve the thermosensitive hydrogel PF-127. The final concentration of the thermosensitive hydrogel PF-127 is 30%. Add appropriate amounts of nanodrug solution to the thermosensitive hydrogel PF-127 and stir evenly to make the final concentration of the hydrogel 20%.

[0071] 4.2 Characterization

[0072] The thermosensitive hydrogel was added to a vial and placed at room temperature for 5 minutes. The flow state was observed by comparing it with the thermosensitive hydrogel just taken out from 4°C. The internal microscopic morphology of the hydrogel was observed using a scanning electron microscope. The rheological properties were detected by measuring the elastic modulus (G') and viscous modulus (G") within 5-40°C using a rheometer. The nanodrug was stained with WGA-CF-594 dye and incubated with HaCaT cells for a gradient time. The release of cell nanovesicles in the thermosensitive hydrogel and their uptake by cells were observed using a laser confocal microscope.

[0073] 5. Animal Experiments

[0074] 5.1 Establishment of a mouse model of deep second-degree burns

[0075] A 20-gram weight was placed in 100°C water and heated for 10 minutes. It was picked up with tweezers and placed on the depilated back skin for 10 seconds to form a circular burn wound of equal size. The mice were randomly divided into 6 groups (n=5 / group), as follows: i) Model group (Model), ii) Blank hydrogel group (Control), iii) Blank vesicle hydrogel group (Free NVs, 27 mg / kg), iv) PD-L1 vesicle hydrogel group (PD-L1 NVs, 27 mg / kg), v) Ai tablet hydrogel group (BO, 10 μg / kg), vi) PD-L1 vesicle loaded Ai tablet hydrogel group (BO@PD-L1 NVs, 27 mg / kg); the burn site was smeared and administered once a day from the third day, and the weight changes of the mice were recorded and the changes in the skin wound area were recorded every day (with the circular mold as the control). Then the wound area was measured using Image J software, and the healing rate was calculated as follows:

[0076] Relative area (A) = wound area / circular mold area (2)

[0077] Healing rate (%) = A 第一天 -A 第n天 / A 第一天 x100%(3)

[0078] All mice were euthanized and further analyzed on day 9. All animal surgeries were approved by the Experimental Animal Ethics Committee of Guangdong Pharmaceutical University (No. SYXK (Guangdong) 2017-0215).

[0079] 5.2 Histopathological analysis

[0080] Skin samples were fixed in 4% paraformaldehyde solution for 48 hours. Tissues were processed in a conventional manner for histological evaluation, and hematoxylin and eosin staining and Masson staining were performed. In addition, immunohistochemical staining for α-SMA and CD3 proteins was performed, and the sections were observed and photographed using a digital slide scanning system.

[0081] 5.3 Detection of T cell activation in spleen and lymph nodes

[0082] The spleen and cervical lymph nodes were made into single cell suspensions, and 100 μL cell staining buffer, 1 μL APC anti-mouse CD4 antibody, 1 μL Brilliant Violet 421TM anti-mouse CD8a antibody, and 1 μL FITC anti-mouse CD3 flow cytometry antibody were added respectively, incubated on ice in the dark for 15 min, and then centrifuged at 1500×g at 4°C for 5 min; the supernatant was discarded, the suspension was resuspended, and the CD4 in the cervical lymph nodes and spleen was measured by flow cytometry. +、CD8 + T cell activation.

[0083] 5.4 Detection of inflammatory factor levels in the healing skin

[0084] Total mRNA was extracted from cells using the standard TRIzol protocol, and RNA concentration and purity were determined. cDNA was prepared using a reverse transcription kit, and qPCR reactions were performed using a qPCR kit and a PCR instrument. -ΔΔCT Methods Analysis of relative quantitative data. Detection of overexpression of mPD-L1 RNA. Primer sequences are as follows:

[0085]

[0086] 6. Statistical Analysis

[0087] GraphPad Prism 7 software was used to perform statistical analysis and graphing of all data in this study. The experimental results are expressed as mean ± standard error (Mean ± SEM). Each group contains at least three replicates. The differences between the two groups were statistically analyzed using the t-test, and the one-way analysis of variance between multiple groups was performed using the Turkey test. P < 0.05 indicates that the difference is statistically significant. (* indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001, and ns indicates P > 0.05, not significant).

[0088] Example 2 Experimental results

[0089] 1. PD-L1 cell nanovesicles were found to be an ideal nanocarrier for loading Ai tablets

[0090] We successfully constructed a cell line that stably overexpressed PD-L1 protein, and the results showed that PD-L1 protein was overexpressed at the mRNA level (Figure 1.B) and protein level (Figure 1.B). Figure 1 .F) confirmed the stability of PD-L1 overexpression and found that PD-L1 protein was stably expressed on the cell membrane ( Figure 1 .A). Further, PD-L1 cell nanovesicles were isolated from cell lines overexpressing PD-L1 protein. By comparing the PD-L1 protein level on PD-L1 cell nanovesicles with that on their source cells ( Figure 1 .F), and found that PD-L1 cell nanovesicles can enrich PD-L1 protein, indicating that its immunosuppressive efficacy is better than that of its source cells. The PD-L1 cell nanovesicles were loaded with low doses of moxa tablets by electroporation to obtain the target nanodrug. Transmission electron microscopy and dynamic light scattering (DLS) analysis showed that the nanoparticles were round structures wrapped in lipid bilayer membranes ( Figure 1 .C), particle size is 90~160nm( Figure 1.E), Zeta potential is -16.19±2.95Mv ( Figure 1 .D), with suitable particle size and stable structure.

[0091] The nanodrug and the unloaded PD-L1 nanovesicles have different morphologies ( Figure 1 .C), particle size (Figure 1.E), Zeta potential ( Figure 1 .D) and PD-L1 protein level ( Figure 1 .F), indicating that the preparation process will not affect its inherent physical characteristics and the stability of PD-L1 expression.

[0092] In general, PD-L1 cell nanovesicles can serve as ideal nanocarriers for loading moxa tablets.

[0093] 2. PD-L1 cell nanovesicles loaded with Ai tablets can inhibit the proliferation of immune cells in vitro

[0094] In order to preliminarily verify the biological activity of PD-L1 cell nanovesicles, Jurkat cells endogenously expressing PD-1 protein were co-incubated with PD-L1 cell nanovesicles and PD-L1 cell nanovesicles loaded with Ai tablets. It was observed that Jurkat cells could effectively take up both vesicles, and the amount of taken up vesicles was comparable ( Figure 2 .A). It proves that PD-L1 cell nanovesicles can bind to target cells expressing PD-1. In addition, it also shows that after electroporation of PD-L1 cell nanovesicles loaded with moxa tablets, their activity of being taken up by cells is not affected, and the binding of PD-L1 to target cells expressing PD-1 can proceed normally.

[0095] Considering that deep second-degree burns are mainly caused by healthy immune cells, we used the isolated PBMCs and T cells to test whether PD-L1 cell nanovesicles also have a significant inhibitory effect. The results of flow cytometry analysis confirmed that PD-L1 protein can significantly inhibit the proliferation of PBMCs and T cells ( Figure 2 .BE). Since PBMCs contain lymphocytes (T cells, B cells, and natural killer cells) and monocytes, the inhibitory effect of PD-L1 on T cell proliferation is stronger than that on PBMCs ( Figure 2 .C). This experiment found that PD-L1 after loading with Ai tablets could still play a role in inhibiting proliferation, but the results of the Ai tablet group were negative.

[0096] 3. PD-L1 cell nanovesicles loaded with Ai tablets can promote the migration of skin cells in vitro

[0097] Since it has been confirmed that PD-L1 cell nanovesicles can inhibit the proliferation of immune cells and thus exert anti-inflammatory effects, whether it can promote the healing of deep second-degree burns still needs to observe its effects on skin-related cells. Therefore, human immortalized keratinocytes (HaCaT) were selected as the target cells for the study and subjected to scratch tests. The results showed that after different treatments with HaCaT, compared with the Ctrl group or Free NVs group, the cell-free areas of the PD-L1 cell nanovesicle group (PD-L1 NVs), the Ai tablet group (BO), and the PD-L1 cell nanovesicle group loaded with Ai tablets (BO@PD-L1 NVs) were visually significantly reduced (Figure 2.G). The statistical results showed that the PD-L1 NVs group, the BO group, and the BO@PD-L1 NVs group significantly promoted the migration of HaCaT cells, and BO@PD-L1 NVs promoted the migration of HaCaT cells more than BO and PD-L1 NVs alone ( Figure 2 .F). On the one hand, it can be explained that both PD-L1 and Ai tablets can inhibit immune factors in the cell growth environment, and the two have a synergistic effect. On the other hand, it may also be that Ai tablets have the effect of promoting cell uptake of drugs, improving the overall efficacy of drugs, and reducing the influence of excessive immune regulatory factors on cell migration after scratching, which will help repair skin wounds.

[0098] 4. Thermosensitive hydrogel can be used as an ideal drug delivery carrier for nanomedicine in the present invention

[0099] The prepared PD-L1 cell nanovesicles loaded with Ai tablets are in a liquid flow state. If they are to be applied for the treatment of deep second-degree burns, they need to be combined with a carrier material that can stably encapsulate the cell nanovesicles. Thermosensitive hydrogels have significant advantages in drug delivery and 3D cell culture, and can stably encapsulate molecular drugs and continuously release them while maintaining their activity.

[0100] First, the physical properties of the thermosensitive hydrogel were investigated. Figure 3 .A- B) shows that the thermosensitive hydrogel can gel in a short time (Figure AI, II). When applied to the wound on the back of the mouse, it can gel on the wound within 30 seconds (Figure A III). Scanning electron microscopy was used to observe that the interior of the thermosensitive hydrogel showed a porous and loose pore structure ( Figure 3 .B), the pore diameter is 50~120μm, this structure is conducive to the encapsulation and release of small molecule drugs such as cell nanovesicles, and also facilitates the free passage of water molecules, which is beneficial to the wound healing process. The rheological properties of the thermosensitive hydrogel were investigated, and the results ( Figure 3.C) It was found that when the elastic modulus (G') = viscous modulus (G"), the sol-gel critical point was reached and large-scale physical network gelation occurred with a gelation temperature of 25.1°C, confirming that the hydrogel could coagulate at the wound when exposed to body temperature and could serve as a barrier to isolate the external environment.

[0101] In order to investigate whether the cell nanovesicles can be released normally after being embedded in the thermosensitive hydrogel and taken up by HaCaT cells, and to study the changes in cell uptake after loading with moxa tablets, we used confocal microscopy to observe and photograph the uptake of thermosensitive hydrogel by HaCaT cells at gradient incubation time points. We found that as the incubation time increased, the fluorescence uptake of the cells gradually increased, reaching the maximum value of cell uptake at 24h, and the fluorescence uptake of the cells at 36h decreased to a certain extent ( Figure 3 .DE). The experimental results show that the thermosensitive hydrogel can slowly and continuously release the cell nanovesicles. The thermosensitive hydrogel can be used as an ideal encapsulation carrier for cell nanovesicles, releasing them into the wound environment to play a role in wound treatment, and acting as a barrier between the external environment and the internal environment of the wound.

[0102] We also found that the relative fluorescence uptake of the PD-L1 cell nanovesicle group loaded with Ai tablets was higher than that of the unloaded group (PD-L1 NVs) at each time point. This result shows that Ai tablets can effectively promote the cellular uptake of small molecule drugs, promote drug absorption and improve bioavailability.

[0103] 5. PD-L1 cell nanovesicles loaded with moxa tablets accelerate wound healing of deep second-degree burns

[0104] We further verified whether nanomedicines can also play an anti-inflammatory role in a physiological environment. We applied the thermosensitive hydrogel embedded with nanomedicine to the wound every day starting from the third day. From the wound pictures, we can observe that PD-L1 cell nanovesicles (PD-L1 NVs), Ai tablets (BO) and PD-L1 cell nanovesicles loaded with Ai tablets (BO@PD-L1 NVs) have a certain promoting effect on wound healing ( Figure 4 .A). By calculating the wound healing rate ( Figure 4 .B), and found that after 9 days of wound repair, the healing rate of the control group (Control), the healing rates of the PD-L1 NVs group and the BO group were 40.10±6.07% and 36.99±9.18%, respectively, while the wound healing rate of the BO@PD-L1 NVs group reached 50.66±10.68%, proving that both PD-L1 cell nanovesicles and Ai tablets have the effect of accelerating the contraction of skin wounds to a certain extent, and the PD-L1 cell nanovesicles loaded with Ai tablets have a synergistic effect and have a better promoting effect.

[0105] Histologically, BO@PD-L1 NVs gel treatment can prevent hyperkeratosis and horn cysts, promote the recovery of skin appendages, have more ideal collagen remodeling and epidermal fibrosis effects, and can inhibit epidermal T cell activation and prevent excessive epidermal inflammatory infiltration ( Figure 4 .C), the efficacy was better than that of using Ai tablets or PD-L1 cell nanovesicles alone.

[0106] The above results show that BO@PD-L1 NVs gel accelerates the wound healing of deep II-degree burns and has a more ideal healing effect.

[0107] 7. PD-L1 cell nanovesicles loaded with Ai tablets can exert synergistic anti-inflammatory effects

[0108] The activation of T cells in mice after nanodrug treatment was investigated, and it was found that compared with the Model group (27.17±0.58%), the Control group (25.13±1.25%) or the Free NVs group (25.47±0.57%), the PD-L1 NVs group (18.40±2.22%), the BO group (19.20±3.48%) and the BO@PD-L1 NVs group (16.90±4.29%) had significantly fewer CD8+T cells in the cervical lymph nodes ( Figure 5 .AC). The BO@PD-L1 NVs group had the most significant reduction effect. However, there was no significant difference in CD8+ T cells in the spleen among the groups. This shows that in the damaged tissue environment, both PD-L1 cell nanovesicles and Ai tablets can negatively regulate T cell activation in the nearby cervical lymphoid tissue, but cannot affect distal lymphoid organs such as the spleen. This confirms that PD-L1 cell nanovesicle loading only negatively regulates T cells in the wound environment, and does not affect the normal immune function in the body. It can specifically inhibit excessive immune responses at the wound and promote skin repair.

[0109] We further explored the changes in inflammatory factors in the burned skin of mice after nanomedicine treatment. It was found that the mRNA levels of IL-1β, IL-6 and TNF-α in the PD-L1NVs group, BO group and BO@PD-L1NVs group were significantly decreased, indicating that both PD-L1 protein and Ai tablets can inhibit inflammation. Moreover, the mRNA level of TNF-α in the BO@PD-L1NVs group decreased more significantly than that in the PD-L1NVs group and BO group, indicating that the PD-L1 cell nanovesicles loaded with Ai tablets can synergistically reduce the level of inflammatory factors in the wound skin ( Figure 5 .D)

[0110] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention. Sequence Listing <110> Guangdong Pharmaceutical University <120> PD-L1 cell nanovesicle drug loaded with Ai tablets and its preparation and application <160> 16 <170> SIPOSequenceListing 1.0 <210> 1 <211> 20 <212> DNA <213> artificial <400> 1 ggctgtattc ccctccatcg 20 <210> 2 <211> twenty two <212> DNA <213> artificial <400> 2 ccagttggta acaatgccat gt 22 <210> 3 <211> 19 <212> DNA <213> artificial <400> 3 ccacactgtg cccatctac 19 <210> 4 <211> twenty four <212> DNA <213> artificial <400> 4 aggatcttca tgaggtagtc agtc 24 <210> 5 <211> 19 <212> DNA <213> artificial <400> 5 gacgcaggcg tttactgct 19 <210> 6 <211> 21 <212> DNA <213> artificial <400> 6 gcggtatggg gcattgactt t 21 <210> 7 <211> 18 <212> DNA <213> artificial <400> 7 ggcatttgct gaacgcat 18 <210> 8 <211> 18 <212> DNA <213> artificial <400> 8 caattagtgc agccaggt 18 <210> 9 <211> 20 <212> DNA <213> artificial <400> 9 ggctgtattc ccctccatcg 20 <210> 10 <211> 22 <212> DNA <213> artificial <400> 10 ccagttggta acaatgccat gt 22 <210> 11 <211> 21 <212> DNA <213> artificial <400> 11 ctgcaagaga cttccatcca g 21 <210> 12 <211> 23 <212> DNA <213> artificial <400> 12 agtggtatag acaggtctgt tgg 23 <210> 13 <211> 22 <212> DNA <213> artificial <400> 13 gaaatgccac cttttgacag tg 22 <210> 14 <211> 21 <212> DNA <213> artificial <400> 14 tggatgctct catcaggaca g 21 <210> 15 <211> 20 <212> DNA <213> artificial <400> 15 ctgaacttcg gggtgatcgg 20 <210> 16 <211> 23 <212> DNA <213> artificial <400> 16 ggcttgycac tcgaattttg aga 23

Claims

1. Application of a PD-L1 cell nanovesicle drug loaded with moxa tablets in the preparation of a drug for treating scalded skin, It is characterized in that The PD-L1 cell nanovesicle drug loaded with Ai tablets comprises PD-L1 cell nanovesicles, and the PD-L1 cell nanovesicles are loaded with Ai tablets; the PD-L1 cell nanovesicle drug loaded with Ai tablets is made of PD-L1 cell nanovesicles and Ai tablets in a weight ratio of 10:10; The PD-L1 cell nanovesicle drug loaded with Ai tablets is prepared by the following method: 1 mg / ml PD-L1 cell nanovesicles are mixed with 1 mg / ml Ai tablet solution, and Ai tablets are loaded into the cell nanovesicles using a MicroPulser electroporator at 300V and 150μF, incubated on ice for 30 minutes, centrifuged at 13500rpm and 4°C for 10 minutes to remove unloaded Ai tablets, and resuspended in PBS to obtain the PD-L1 cell nanovesicle drug solution loaded with Ai tablets; The preparation method of the PD-L1 cell nanovesicle comprises: using PEI transfection reagent, mouse / human CD274 gene lentiviral cDNA expression plasmid and packaging plasmid to prepare a recombinant lentiviral vector, infecting target cells to construct a transfected cell line that stably overexpresses the PD-L1 gene; after culture and amplification, using HM lysis solution to lyse the cells, using a tissue grinder to fully grind and break the cells, and centrifuging at 5000rpm and 4°C for 10min to remove the cell nucleus and other impurities; centrifuging at 12000rpm and 4°C for 10min to obtain a cell membrane precipitate; then filtering through filter membranes with pore sizes of 0.45μm, 0.22μm and 0.11μm to compress the cell membrane structure into a vesicle, thereby obtaining the PD-L1 cell nanovesicle; using Bradford protein quantification reagent to determine the protein amount and adjust the concentration of the PD-L1 cell nanovesicle to 1mg / ml; the preparation method of the 1mg / mL Ai tablet solution comprises: grinding the Ai tablet into powder, weighing 10mg of Ai tablet, dissolving it in 10μL DMSO, and adding 1mL in portions PBS, sonicate the centrifuge tube for 5 minutes to help dissolve, to a total volume of 10 mL, to obtain a 1 mg / mL solution of Ai tablets; The medicine for treating scalded skin trauma also contains Pluronic F-127 temperature-sensitive hydrogel.

2. The use according to claim 1, It is characterized in that The concentration of Pluronic F-127 temperature-sensitive hydrogel in the medicine for treating scalded skin trauma is 20%.

3. The use according to claim 2, It is characterized in that The preparation process of the drug for treating scalded skin trauma includes weighing 30g of thermosensitive hydrogel Pluronic F-127 powder, adding 100mL PBS, and stirring overnight on a stirrer in a 4°C refrigerator to completely dissolve the thermosensitive hydrogel, and the final concentration of the thermosensitive hydrogel is 30%; under 4°C, adding an appropriate amount of PD-L1 cell nanovesicle drug solution loaded with Ai tablets to the thermosensitive hydrogel, stirring evenly, so that the final concentration of the hydrogel is 20%.